quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·57d
PRRelease
PMV Pharmaceuticals Inc. logo

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PMVP· PMV Pharmaceuticals Inc.
Health Care
Original source

Companies

  • PMVP
    PMV Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Nov 8UpdateOppenheimer$6.00
  • May 13UpdateCraig Hallum$6.00
  • Apr 12UpdateJefferies$5.00
  • Dec 27UpdateLadenburg Thalmann$7.00
  • Mar 2UpdateOppenheimer$30.00
  • Mar 2UpdateOppenheimer-

Related

  • SEC2d
    SEC Form DEFA14A filed by PMV Pharmaceuticals Inc.
  • SEC2d
    SEC Form DEF 14A filed by PMV Pharmaceuticals Inc.
  • PR2d
    PMV Pharmaceuticals Announces Board Chair Transition
  • INSIDER45d
    SEC Form 4 filed by Chief Financial Officer Carulli Michael
  • INSIDER45d
    SEC Form 4 filed by General Counsel & COO Ticktin Robert
  • INSIDER45d
    SEC Form 4 filed by Chief Development Officer Jalota Deepika
  • INSIDER45d
    SEC Form 4 filed by President and CEO Mack David Henry
  • SEC49d
    SEC Form S-8 filed by PMV Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022